Group 1 - The article promotes a portfolio strategy that generates income without the need for selling assets, aiming to simplify retirement investing [1][2] - It emphasizes community and education, suggesting that investors should not navigate the investment landscape alone [2] - The service offers features such as model portfolios, buy/sell alerts, and regular market updates to support investors [2][4] Group 2 - The article mentions the involvement of contributors who provide insights and recommendations, indicating a collaborative approach to investment strategies [4] - It highlights the importance of monitoring positions and issuing alerts to members, ensuring active management of investments [4]

Core Insights - Fractyl Health's Rejuva platform shows promise as a one-time, durable therapy for obesity and type 2 diabetes (T2D), demonstrating a favorable toxicity profile in preclinical studies [1][2][4] - The mechanism of action for Rejuva is distinct from systemic GLP-1 receptor agonists, allowing for nutrient-responsive secretion that activates only under metabolic stress [2][3] - Preliminary clinical data for RJVA-001, the first clinical candidate from the Rejuva platform, is expected in 2026, pending regulatory authorization [5][11] Key Findings - A single dose of Rejuva in a study with mice resulted in a 20% reduction in body weight and a 38% decrease in blood glucose levels by day 21, effects maintained despite continued high-fat diet exposure [7] - Rejuva-treated lean animals showed no weight gain or hyperglycemia when switched to a high-fat diet, maintaining baseline body weight and showing an 8% reduction in blood glucose [7] - The treatment was well-tolerated with no signs of toxicity or excessive weight loss in healthy animals, reinforcing the self-limiting nature of Rejuva's mechanism [7] Momentum Toward the Clinic - Fractyl Health has completed key in vivo studies for RJVA-001 and anticipates dosing the first patients in 2026, aiming for a first-in-class gene therapy that reprograms the pancreas for natural metabolic control [5][11] Scientific Validation - The study was conducted by a team from Fractyl Health and the University of Michigan, including experts in metabolic diseases, highlighting the scientific momentum behind Rejuva's approach [6][8]

Core Viewpoint - Aero Energy Limited has successfully completed the acquisition of Kraken Energy Corp, creating a leading North American uranium developer by combining their respective assets and strengths [1][2]. Company Overview - The merger combines Aero's 250,000-acre land package in Saskatchewan's Athabasca Basin with Kraken's high-grade uranium properties in the U.S., including the Apex Uranium Property, Nevada's largest past-producing uranium mine [12]. - The new entity aims to unlock high-grade, unconformity-style mineralization and capitalize on the growing demand for uranium [12]. Transaction Details - Under the terms of the arrangement, all issued and outstanding Kraken Shares were exchanged for a total of 57,922,329 common shares of Aero at an exchange ratio of 0.97037 Aero Shares for each Kraken Share [3]. - Following the completion of the arrangement, Aero has 179,849,606 shares issued and outstanding, with approximately 67.79% held by Aero's shareholders prior to the arrangement and 32.21% by former Kraken shareholders [3]. Leadership Changes - The board of directors of Aero post-merger consists of five members, including three existing Aero directors and two nominees from Kraken [5]. - Galen McNamara continues as CEO and Director of Aero, with Carson Halliday appointed as CFO and Corporate Secretary [5]. Regulatory Approvals - The Supreme Court of British Columbia approved the arrangement on June 17, 2025, and the shareholders of Kraken approved the transaction at their annual general and special meeting on June 11, 2025 [2][3]. Market Impact - The merger is expected to enhance the companies' ability to unlock permits and scale operations effectively, positioning them to capture momentum in the uranium market [2]. - The Kraken Shares are anticipated to be de-listed from the Canadian Securities Exchange effective June 20, 2025, and Aero plans to terminate Kraken's public reporting obligations [8].

Core Viewpoint - NFI Group Inc. is expanding its partnership with Brampton Transit by delivering 55 new Xcelsior buses, which includes both hybrid-electric and clean-diesel models, to enhance the city's transit fleet and support sustainable mobility solutions [2][3]. Group 1: Company Overview - NFI Group Inc. is a leader in propulsion-agnostic bus and coach mobility solutions, with a broad product portfolio that includes electric and hybrid models [5][8]. - The company has a significant presence in the bus manufacturing industry, employing nearly 9,000 team members across ten countries and supporting over 100,000 buses and coaches globally [6][7]. Group 2: Recent Developments - The new order for Brampton Transit consists of 20 hybrid-electric 40-foot buses and 35 clean-diesel 60-foot buses, totaling 70 equivalent units, which will be added to New Flyer's second quarter 2025 backlog [2]. - This order marks a continuation of a long-term relationship, with over 300 buses delivered to Brampton over the past 30 years, highlighting the company's commitment to innovative mobility solutions [3]. Group 3: Product Benefits - New Flyer's Xcelsior buses are designed to provide improved fuel efficiency, reduced emissions, and strong operational reliability, making them suitable for modern transit needs [4]. - The buses utilize advanced engines and ultra-low sulfur diesel, contributing to sustainable transportation solutions that support community growth [4].

– NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES –Vancouver, BC, June 23, 2025 (GLOBE NEWSWIRE) -- New Wave Holdings Corp., to be renamed Humanoid Global Holdings Corp., (“New Wave” or the “Company”) (CSE:NWAI, FWB:0XM0, OTCPK:TRMNF) is pleased to announce that it will proceed with a non-brokered private placement of up to 10,000,000 units of the Company (the “Units”) at $0.30 per Unit for gross proceeds of up to $3,000,000 (the “Offering”).Each Unit will consist of one common ...

Enrollment of 51 subjects highlights significant unmet need in this serious, lifelong genetic disease which currently has no FDA-approved therapies Top-line data expected in the first quarter of 2026 WAYNE, Pa., June 23, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PVLA) Palvella Therapeutics, Inc. (Palvella), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no U.S. Food and Drug ...

SHANGHAI and HONG KONG, June 23, 2025 (GLOBE NEWSWIRE) -- NETCLASS Technology INC (Nasdaq: NTCL; the “Company” or “NetClass”), a leading B2B smart education IT solutions provider with offices in Shanghai, Hong Kong, Singapore and Tokyo, is pleased to announce that it signed a Framework Agreement for Cooperation with Nanyang Institute of Social Sciences Ptd. Ltd. (“Nanyang Institute of Social Sciences”), a private higher education institution registered with Singapore’s Ministry of Education, to mark the beg ...

Proposed reverse merger with OrthoCellix, a wholly-owned subsidiary of Ocugen, to create Nasdaq-listed, late clinical-stage regenerative cell therapy company with a first-in-class technology platform, focused on orthopedic diseasesOrthoCellix is developing the Phase 3-ready NeoCart® as an autologous cartilage implant technology utilizing patient cells to repair articular cartilage defects of the knee PHILADELPHIA and MALVERN, Pa., June 23, 2025 (GLOBE NEWSWIRE) -- Carisma Therapeutics Inc. (Nasdaq: CARM) (C ...

BERKELEY HEIGHTS, N.J., June 23, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announces an update related to its Large Dialysis Organization (LDO) customer and planned implementation in the second half of 2025. CorMedix’s LDO customer has commenced ordering and will begin the implementation of DefenCath in its patients. Implementation will initially target ...

Join iREIT on Alpha today to get the most in-depth research that includes REITs, mREITs, Preferreds, BDCs, MLPs, ETFs, and other income alternatives. 438 testimonials and most are 5 stars. Nothing to lose with our FREE 2-week trial .I didn't predict the war between Iran and Israel, and I also did not predict the severity of the trade war. However, I was right about markets struggling with negative headlines and the fact that both rates and inflationAnalyst’s Disclosure:I/we have a beneficial long position i ...